In summary, although there is no therapy designed to directly target COL11A1, potential therapeutic strategies for COL11A1-high cancers include targeting COL11A1 transcription by inhibiting TGF-β and c/EBPβ (Galunisertib/SR-T100), COL11A1 secretion (HSP47 inhibitor AK778/Col003), COL11A1 receptors DDR2 and integrin α1β1 (Dasatinib and SAN-300), Akt activation (AZD5363, SC66), IAPs (Birinapant), or FAO enzymes (Perhexiline, ranolazine, and Trimetazidine). Here, DDR2 is linked to cancer.